ADVERTISEMENT

Business

U.S. pharma bets big on China to snap up potential blockbuster drugs

Published

U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data, betting they can turn upfront payments of as little as US$80 million into multibillion-dollar treatments.. Photographer: Carsten Snejbjerg/Bloomberg (Carsten Snejbjerg/Bloomberg)